CATEGORIES: Research | Vitaccess

CMT&ME APP Adds New Medical Profile

by | Jan 6, 2020 | 0 comments

Did you know you can now store your CMT data at your fingertips? The CMT&ME app, developed by Vitaccess, has updated the app to include a brand new medical profile. To update the app, go to your app store and click update. 

In collaboration with our industry partners Pharnext and Vitaccess, we are thrilled to bring to you new features of the CMT&Me App. 

“This two-year study, which has been launched in 6 countries, was built for you and by you, the patients,” says Dr. Youcef Boutalbi, Pharnext Medical Affairs Director at the groundbreaking HNF Movement is Medicine™ Summit Crowd-Design Workshop on November 8-9, 2019. 

Currently this is the only mobile App for patients to record details on their diagnosis, list current or prior medications or participation in clinical trials, and log in regularly to report on symptoms, such as pain, falls, sleep, and so much more. 

This vital partnership gives our members the opportunity for their voices to be heard! By sharing your daily or weekly experiences and challenges, you are participating in very important research that will help Pharnext and the entire CMT community accelerate therapies to address your unmet medical needs, expand the knowledge of what you, as patients, face. Most importantly, it will provide a portal to store your data to refer back to or even share with your doctors. 

Allison Moore, Founder and CEO of HNF, has worked closely with Dr. Mark Larkin, Founder and CEO of Vitaccess, to disseminate CMT&Me research findings at global medical conferences to increase awareness of the CMT patient experience and advise regulators and payers (ie. insurance companies) on the impact CMT has on quality of life. The latest poster sessions Mark and Allison were highlighted at the AANEM annual conference in Austin, TX. 

  • Diversity in the Charcot-MarieTooth Disease Population in the United Kingdom and United States: Insights from a Digital Real-World Observational Study 
  • Treatment of Charcot-Marie-Tooth Disease in the United Kingdom and United States: Insights from a Digital Real-World Observational Study 

The CMT&Me App has shed additional insights into this grossly underserved community and the unmet need of medical care and treatments for our patient community. Pharnext, Vitaccess and HNF recognize the urgency of getting drugs approved and commercialized for CMT, so don’t wait, join today! 

CLICK HERE FOR MORE INFORMATION: www.hnf-cure.org/living-with-cmt/cmtme-study 

DOWNLOAD THE CMT ME APP TODAY! www.hnf-cure.org/cmtme-study

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news